Novartis gets US FDA nod for Rhapsido to treat symptomatic dermographism; expanding its use beyond chronic spontaneous urticaria: Basel Friday, October 9, 2026, 15:00 Hrs [IST] No ...
Two weeks after undergoing a biopsy to investigate a mysterious rash on her arm, a pregnant woman from Queensland, Australia ...
The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism who remain symptomatic despite use of ...
The approval will allow the drugmaker to expand the use of its Bruton tyrosine kinase inhibitor, already approved for chronic ...
Remibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi), was approved for the treatment of chronic spontaneous ...
Enjoying the outdoors carries the danger of running into nature’s less-friendly side: toxic plants and animals.
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication, symptomatic ...
Approval builds on established role of Rhapsido in CSU and highlights potential of BTK inhibition across immune-mediated ...
A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...
When red bumps suddenly spread all over your body, you might feel anxious, wondering, "Is it an allergy?" or "Should I go to ...
A recent study shows one-in-five people in Hong Kong have suffered from urticaria, otherwise known as hives.Around 65% say ...
WHEN Kimberley Brown first noticed a “burning sensation” near her armpit that wouldn’t disappear, she rang her GP surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results